欧洲人体纤维蛋白胶市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲人体纤维蛋白胶市场 – 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • Nov 2021
  • Europe
  • 350 页面
  • 桌子數: 82
  • 图号: 35

欧洲人体纤维蛋白胶市场,按包装形式(液体、贴片、其他)、应用(心脏外科、肺外科、烧伤出血、血管外科、整形外科、肝脾撕裂伤、神经外科、整形外科、普通外科、伤口管理、其他)、分销渠道(直接招标和零售销售)、最终用户(医院、门诊护理中心、专科诊所、其他)、国家(德国、法国、英国、意大利、西班牙、俄罗斯、荷兰、瑞士、土耳其、奥地利、比利时、欧洲其他地区)行业趋势和预测到 2029 年。

欧洲人体纤维蛋白胶市场市场分析和见解:欧洲人体纤维蛋白胶市场

预计欧洲人体纤维蛋白胶市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称,在 2022 年至 2029 年的预测期内,市场将以 9.0% 的复合年增长率增长,预计到 2029 年将达到 2.1404 亿美元。产品开发的增加和早期诊断需求的增加是推动预测期内市场需求的主要驱动因素。然而,严格的监管阻碍了市场的增长。

人纤维蛋白胶参与止血和伤口愈合过程。人纤维蛋白胶 (HFG) 由装在单独小瓶中的两种成分制成:凝血蛋白的冷冻干燥浓缩物,主要包括纤维蛋白原、因子 XIII 和纤连蛋白(密封剂),以及冷冻干燥凝血酶(催化剂),可涂抹在伤口上或手术期间,以避免失血,形成凝块以止血,减少住院时间并减少疤痕。

FDA 批准的增加和主要市场参与者的存在预计将促进市场增长。政府投资的增加和民众意识的提高使市场能够改善治疗。然而,产品召回的增加预计将对市场构成挑战。

人纤维蛋白胶市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预​​期目标。

欧洲人体纤维蛋白胶市场欧洲人体纤维蛋白胶市场范围和市场规模

根据包装形式、应用、最终用户和分销渠道,人纤维蛋白胶市场可分为四个显著的细分市场。细分市场之间的增长有助于您分析利基市场的增长空间和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据包装形式,人纤维蛋白胶市场分为液体、贴剂和其他类型。由于政府在医疗保健方面的支出增加,预计 2022 年液体类型将主导欧洲人纤维蛋白胶市场。
  • 根据应用,人纤维蛋白胶市场细分为心脏手术、肺部手术、烧伤出血、血管手术、骨科手术、肝脾裂伤、神经外科、整形外科、普通外科、伤口处理等。2022 年,随着该地区外科手术的增加,伤口处理领域预计将主导欧洲人纤维蛋白胶市场。
  • 根据最终用户,人体纤维蛋白胶市场分为医院、门诊中心、专科诊所和其他。由于人体纤维蛋白胶需求不断增长,预计 2022 年医院市场将占据主导地位。
  • 根据分销渠道,人体纤维蛋白胶市场分为直接招标和零售。2022 年,预计直接招标部分将进入人体纤维蛋白胶市场,主要市场参与者将参与其中。

 人纤维蛋白胶市场国家层面分析

对人体纤维蛋白胶市场进行了分析,并根据包装形式、应用、最终用户和分销渠道提供了市场规模信息。

人体纤维蛋白胶市场报告涉及的国家包括德国、英国、法国、意大利、西班牙、荷兰、俄罗斯、瑞士、比利时、土耳其和欧洲其他地区。

由于医疗保健行业研发的增长,德国有望主导欧洲人体纤维蛋白胶市场。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

医疗支出的增加推动了人纤维蛋白胶市场的增长

人纤维蛋白胶市场还为您提供有关人纤维蛋白胶行业每个国家增长情况的详细市场分析,包括人纤维蛋白胶销售、人纤维蛋白胶技术进步的影响以及监管环境的变化及其对人纤维蛋白胶市场的支持。数据涵盖 2010 年至 2020 年的历史时期。

竞争格局和人纤维蛋白胶市场份额分析

人纤维蛋白胶市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对人纤维蛋白胶市场的关注有关。

一些在欧洲人纤维蛋白胶市场经营的主要公司包括强生服务公司、百特、CSL 有限公司和 Corza Health。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。

全球各地的公司也纷纷推出新产品并签订协议,这也加速了人体纤维蛋白胶市场的发展。

例如,

  • 2021 年 2 月,Corza Health 收购并合并了 Surgical Specialties Corporation(“Surgical Specialties”)和 TachoSil Fibrin Sealant Patch(“TachoSil”),成立了一家新公司 Corza Medical。此次合并增加了公司的产品组合和销售额。

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在人体纤维蛋白胶市场的市场,这也为组织改善其人体纤维蛋白胶供应提供了好处。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE HUMAN FIBRIN GLUE (HFG) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PACKAGE FORM LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 INDUSTRY INSIGHTS

6 REGULATORY ANALYSIS

6.1.1 REGULATION IN U.S.

6.1.2 REGULATION IN EUROPE

6.1.3 REGULATION IN AUSTRALIA

6.1.4 REGULATION IN CANADA

6.1.5 REGULATION IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN TECHNOLOGICAL ADVANCEMENT

7.1.2 INCREASING SURGICAL PROCEDURES

7.1.3 ADVANTAGES OF HUMAN FIBRIN GLUE

7.1.4 INCREASE IN THE GERIATRIC POPULATION

7.1.5 SUPERIORITY OF FIBRIN SEALANTS, OVER LIMITATIONS OF CONVENTIONAL METHODS

7.2 RESTRAINTS

7.2.1 STRINGENT RULES & REGULATORY

7.2.2 HIGH COST OF PRODUCTS

7.2.3 RISK OF VIRAL INFECTIONS

7.3 OPPORTUNITIES

7.3.1 INCREASE IN PREVALENCE OF CHRONIC DISORDERS

7.3.2 RISE IN MINIMALLY INVASIVE SURGERIES

7.3.3 RISING PLASTIC SURGERIES

7.4 CHALLENGES

7.4.1 COMPLICATION RELATED TO USE OF HUMAN FIBRIN GLUE

7.4.2 LACK OF SKILLED PROFESSIONALS

7.4.3 DECREASED SURGICAL PROCEDURES DUE TO COVID-19

8 IMPACT OF COVID-19 ON EUROPE HUMAN FIBRIN GLUE (HFG) MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON SUPPLY CHAIN

8.3 IMPACT ON DEMAND

8.4 CONCLUSION

9 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM

9.1 OVERVIEW

9.2 LIQUID

9.2.1 1-2 ML

9.2.2 7-10 ML

9.2.3 3-4 ML

9.2.4 5-6 ML

9.3 PATCH

9.4 OTHERS

10 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 SPECIALTY CLINICS

10.4 AMBULATORY CARE CENTER

10.5 OTHERS

11 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

12 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 WOUND MANAGEMENT

12.3 BURN BLEEDING

12.4 PLASTIC SURGERY

12.5 GENERAL SURGERY

12.6 VASCULAR SURGERIES

12.7 LACERATIONS OF LIVER AND SPLEEN

12.8 CARDIAC SURGERY

12.9 PULMONARY SURGERY

12.1 ORTHOPEDIC SURGERIES

12.11 NEUROSURGERY

12.12 OTHERS

13 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION

13.1 EUROPE

13.1.1 GERMANY

13.1.2 U.K.

13.1.3 FRANCE

13.1.4 ITALY

13.1.5 SPAIN

13.1.6 SWITZERLAND

13.1.7 RUSSIA

13.1.8 NETHERLANDS

13.1.9 TURKEY

13.1.10 BELGIUM

13.1.11 REST OF EUROPE

14 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 CSL LIMITED

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 JOHNSON & JOHNSON SERVICES, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 BAXTER

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 HUALAN BIOLOGICAL ENGINEERING, ING

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 SHANGHAI RAAS

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 CORZA HEALTH

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 MARQUEE BIOSURGICAL

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表格列表

TABLE 1 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 2 EUROPE LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 4 EUROPE PATCH IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE OTHERS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 7 EUROPE HOSPITALS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 EUROPE SPECIALTY CLINICS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 9 EUROPE AMBULATORY CARE CENTERS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 10 EUROPE OTHERS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 11 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 12 EUROPE DIRECT TENDER IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE RETAIL SALES IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE WOUND MANAGEMENT IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE BURN BLEEDING IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE PLASTIC SURGERY IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE GENERAL SURGERY IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE VASCULAR SURGERIES IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE LACERATIONS OF LIVER AND SPLEEN IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE CARDIAC SURGERY IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE PULMONARY SURGERY IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE ORTHOPEDIC SURGERIES IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE NEUROSURGERY IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE OTHERS IN HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 27 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 28 EUROPE LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 29 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 31 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 GERMANY HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 33 GERMANY LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 34 GERMANY HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 35 GERMANY HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 36 GERMANY HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 U.K. HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 38 U.K. LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 39 U.K. HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 U.K. HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 41 U.K. HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 FRANCE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 43 FRANCE LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 44 FRANCE HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 FRANCE HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 46 FRANCE HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 ITALY HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 48 ITALY LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 49 ITALY HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 ITALY HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 51 ITALY HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 52 SPAIN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 53 SPAIN LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 54 SPAIN HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 55 SPAIN HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 56 SPAIN HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 57 SWITZERLAND HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 58 SWITZERLAND LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 59 SWITZERLAND HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 SWITZERLAND HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 61 SWITZERLAND HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 62 RUSSIA HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 63 RUSSIA LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 64 RUSSIA HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 RUSSIA HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 66 RUSSIA HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 67 NETHERLANDS HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 68 NETHERLANDS LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 69 NETHERLANDS HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 NETHERLANDS HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 71 NETHERLANDS HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 TURKEY HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 73 TURKEY LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 74 TURKEY HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 TURKEY HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 76 TURKEY HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 BELGIUM HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 78 BELGIUM LIQUID IN HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

TABLE 79 BELGIUM HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 80 BELGIUM HUMAN FIBRIN GLUE (HFG) MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 81 BELGIUM HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 82 REST OF EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: SEGMENTATION

FIGURE 2 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN DEMAND FOR HUMAN FIBRIN GLUES ARE EXPECTED TO DRIVE THE EUROPE HUMAN FIBRIN GLUE (HFG) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 LIQUID IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HUMAN FIBRIN GLUE (HFG) MARKET IN 2022 AND 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HUMAN FIBRIN GLUE (HFG) MARKET

FIGURE 14 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY PACKAGE FORM, 2021

FIGURE 15 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY PACKAGE FORM, 2022-2029 (USD MILLION)

FIGURE 16 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY PACKAGE FORM, CAGR (2022-2029)

FIGURE 17 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY PACKAGE FORM, LIFELINE CURVE

FIGURE 18 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY END USER, 2021

FIGURE 19 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 20 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 21 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY END USER, LIFELINE CURVE

FIGURE 22 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 23 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 24 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 25 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 26 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY APPLICATION, 2021

FIGURE 27 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 29 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 30 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET : SNAPSHOT (2021)

FIGURE 31 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET : BY COUNTRY (2021)

FIGURE 32 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET : BY COUNTRY (2022 & 2029)

FIGURE 33 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET : BY COUNTRY (2021 & 2029)

FIGURE 34 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET : BY PACKAGE FORM (2022-2029)

FIGURE 35 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

Europe Human Fibrin Glue Market is to witness a raise of 9.0% in CAGR forecast by 2029.
Europe Human Fibrin Glue Market will skyrocket its value by $214.04 million by 2029.
The countries focused on the Europe Human Fibrin Glue Market report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, and the rest of Europe.
The key player in the Europe Human Fibrin Glue Market are Johnson & Johnson Services, Inc., Baxter, CSL Limited, and Corza Health.